The rise of Viagra initially sparked a surge for major pharmaceutical companies, however recent shifts present a murky scenario for shareholders. Off-patent alternatives are eroding profits, and persistent legal battles add further risk to read more the equation. While certain companies could still gain from complementary products, the broader traj